ERGOLINE ERGOLINE HYDERGINE HYDERGINE HYDERGINE HYDERGINE CEREGIN CEREGIN ERGOVAS-3

Dose: 0.3 mg
Single Dose: 0.3 (0.3)
Frequency: 12 hourly
Route: IM
Instructions: For one week. Followed by oral therapy

. It is of Synthetic origin and belongs to Ergot Alkaloid. It belongs to Psychotherapeutic Drugs and Ergot Derivative pharmacological group.The Molecular Weight of Co-Dergocrine Mesylate is 659.80.

Co-Dergocrine Mesylate is contraindicated in conditions like Hypersensitivity.

The symptomatic adverse reactions produced by Co-Dergocrine Mesylate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, GI upset, Nasal stiffiness.

Co-Dergocrine Mesylate is primarily indicated in conditions like Cerebral insufficiency, Dementia, Dizziness, Headache, Impaired memory, Migraine, Vascular headaches.

No data regarding the interactions of Co-Dergocrine Mesylate was found.

Drug should not be given to Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tab Protect from Sunlight.

Co-Dergocrine Mesylate should be used with caution in patients with severe bradycardia. Blood pressure should be checked following parentral administration as a drop in blood pressure may occur. It is classified as pregnancy category C and should be used during prgnancy only if clearly needed.